Birchview Capital, LP Cytokinetics Inc Transaction History
Birchview Capital, LP
- $111 Million
- Q1 2025
A detailed history of Birchview Capital, LP transactions in Cytokinetics Inc stock. As of the latest transaction made, Birchview Capital, LP holds 10,000 shares of CYTK stock, worth $310,200. This represents 0.36% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$310,200
Previous $470,000
14.68%
% of portfolio
0.36%
Previous 0.4%
Shares
5 transactions
Others Institutions Holding CYTK
# of Institutions
408Shares Held
127MCall Options Held
3.66MPut Options Held
900K-
Black Rock Inc. New York, NY14.7MShares$455 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$368 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.96MShares$309 Million0.26% of portfolio
-
Wellington Management Group LLP Boston, MA7.99MShares$248 Million0.06% of portfolio
-
State Street Corp Boston, MA6.09MShares$189 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $2.92B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...